The study associated with this evidence worked with individuals who had ectodermal dysplasia of varying age groups of up to 11, 11 to 18 and more than 18 years. It was noted that the risk of implant failure was significantly higher in patients younger than 18 years, but there is significant reason to use this methodology of treatment in those older. Overall the use of an implant-prosthesis has a considerable functional, aesthetic and psychological advantage when compared to a conventional denture, in the patients. Prognosis
Patients diagnosed with anodontia are expected to have a normal life expectancy. Once anodontia is diagnosed, dental implants or dentures will need to worn in order to treat this disorder. There is an 88.5% to 100% chance for dental implants in patients with ectodermal dysplasia or tooth agenesis to be successful when placed after the age of 18. Epidemiology
The prevalence of anodontia is unknown but it is a very rare disorder. Anodontia occurs in less than 2-8% of the general population in regards to permanent teeth and 0.1-0.7% in primary teeth. Gender and ethnicity do not play a role in anodontia. Research
A recent study in 2019 by R. Constance Wiener and Christopher water looked at anodontia, hypodontia, and oligodontia in children West Virginia. There is a high prevalence of children with missing permanent teeth in West Virginia compared to the rest of the nation. During this study, 500 panoramic images were taken of children between the ages of 6 to 11.
A study administering ganirelix to healthy adult females (n=15) found the mean (SD) elimination half-life (t1/2) to be 16.2(1.6) hours, volume of distribution/absolute bioavailability (Vd/F) 76.5(10.3) liters, maximum serum concentration (Cmax) 11.2(2.4) ng/mL, and the time until maximum concentration (tmax) 1.1(0.2) hours. One 250 µg injection of ganirelix resulted in a mean absolute bioavailability of 91.1%. Chemistry
Ganirelix is derived from GnRH, with amino acid substitutions made at positions 1, 2, 3, 6, 8, and 10. History
The European Commission gave marketing authorization for ganirelix throughout the European Union to N.V. Organon in May 2000. See also
Gonadotropin-releasing hormone receptor § Antagonists

References
External links
"Ganirelix". Drug Information Portal. U.S. National Library of Medicine. "Ganirelix acetate". Drug Information Portal. U.S. National Library of Medicine.